drugset / Trial / NCT01849289

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

NCT01849289

Phase 3 Completed 833 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.

Timeline

Start
2013-06-02
Primary completion
2014-05-15
Completion
2014-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin degludec Protein / enzyme biologic Subcutaneous
Subject insulin glargine Protein / enzyme biologic Subcutaneous